MSD Animal Health Receives Marketing Approval from European Medicines Agency for BRAVECTO™ (fluralaner) Spot-On Solution for Cats and Dogs

Dateline City: MADISON, N.J. Spot-On Treatment for Fleas and Ticks Effective For 12 Weeks MADISON, N.J.--(BUSINESS WIRE)--MSD Animal Health (known as Merck Animal Health in the United States and Canada) today announced that, following a positive opinion from the Committee for Medicinal Products for Veterinary Use (CVMP), the European Medicine Agency has granted a marketing authorization for the veterinary medicinal product BRAVECTO™ (fluralaner) Spot-On Solution for both cats and dogs, a Spot-On treatment for fleas and ticks effective for 12 weeks following a single dose. Language: English Contact: MSD Animal HealthMedia:Amy Firsching, +1 973 937 5453amy.firsching@merck.comorPam Eisele, 267-305-3558pamela_eisele@merck.com Ticker Slug: Ticker: MRK Exchange: NYSE read more
Source: Merck - Category: Pharmaceuticals Tags: Animal Health #MSD $MRK Bravecto MSD Animal Health Source Type: news